CD274 and neoplasm: Accumulating evidence has implicated various biomarkers in predicting responsiveness to ICIs in NSCLC, including tumor mutational burden (TMB) [5], programmed death ligand-1 (PD-L1) expression [6], tumor-infiltrating lymphocyte (TIL) density [7], and inflammatory cytokine profiles [8].